Urokinase (Urokinase)

Urokinase is an enzyme produced by the kidneys that plays an important role in dissolving blood clots, preventing blood clots and improving circulation. In medicine, urokinase is used to treat various diseases associated with thrombosis, such as pulmonary embolism, deep vein thrombosis, acute myocardial infarction and others.

Urokinase activates plasminogen, which is the main enzyme responsible for dissolving blood clots. This process is called fibrinolysis. Urokinase is administered intravenously or intramuscularly to quickly achieve maximum concentration in the blood.

However, urokinase has its limitations. It only works for a short time and may not dissolve all types of blood clots. Therefore, its use should be prescribed by a doctor and monitored during treatment.

In general, urokinase is an effective treatment for thrombosis, but its use should be based on individual indications and under the supervision of a physician.

Urokinase is an enzyme produced by the kidneys that is involved in dissolving blood clots. This enzyme is called urokinase because it stimulates the conversion of plasminogen (the enzyme that breaks down blood clots) into plasmin (the enzyme that actually breaks down blood clots).

Urokinase is particularly useful in the treatment of pulmonary embolism and deep vein thrombosis. It can also be used in acute myocardial infarction.

However, like all medications, urokinase has its side effects and contraindications. Therefore, you should consult your doctor before using this drug.

**Urinizines** Fibrinolytic agent Used to dissolve remnants of emboli and blood clots after angioplasty and surgery for atherosclerosis and complicated angina. It is a dry microcellular mass containing urokinase, obtained by extracting from cilantro through two-stage extraction with aqueous-alcohol solutions. The activity of the drug depends on the time of its use - after 8 hours of storage in a hypertonic NaCl solution, the activity drops by 2 times. To avoid loss of activity and changes in physicochemical properties, the drug should be dissolved in saline twice.

Urokinase activity can be used to predict the effectiveness of intravascular treatment. In order to maintain activity during long-term storage of the urokinase solution, it is recommended to infiltrate the skin at the injection site and keep it under a generous cold compress. Duration of action is about 12 hours. Accelerates the lysis of hemorrhagic formations. Reduces blood clotting during the first 2 days of treatment. The recurrent nature of bleeding is not detected. The use of urokinase is accompanied by the development of allergic reactions, an increase or decrease in the activity of liver transaminases, and an acceleration of ESR.